Biosimilars are reshaping healthcare; expanding access, challenging established markets, and creating new pathways for growth. But beyond science and strategy lies a bigger question: how do we turn opportunity into lasting impact? This panel brings together leaders from across the ecosystem to share perspectives on the evolving biosimilar landscape and what it takes to thrive within it. The discussion explores ambition and responsibility, highlighting the importance of collaboration, strategic execution, and sustainable value creation in a rapidly changing global environment.
Tuesday, May 5, 16:00 - 16:45, room Shanghai 1+2
| Name | Position | Institution |
|---|---|---|
| Dr. Haleh Hamedifar | Chairperson of CinnaGen | |
CinnaGen, founded in 1994, is the leading biotechnology and biopharmaceutical company in the Middle East and North Africa (MENA). Renowned for its high-quality and diverse portfolio of biosimilars, recombinant proteins, monoclonal antibodies, therapeutic enzymes, and diagnostic reagents, CinnaGen serves markets across MENA, CIS, LATAM, and beyond. With EU‑GMP–certified facilities and a strong global presence, CinnaGen exemplifies excellence in biopharmaceutical development and delivery, setting new standards for accessible, life-enhancing therapies worldwide.
